Business

Know the Business

CooperCompanies is two businesses glued together by a disciplined capital allocator. The larger one — CooperVision — is a genuinely advantaged contact-lens oligopolist with a consumable revenue model and pricing power through prescribing eye-care professionals. The smaller one — CooperSurgical — is a roll-up in IVF and women's health whose economics hinge on one irreplaceable product (Paragard) and a long integration runway. The market is underpricing the durability of the lens franchise and overpricing the idea that CSI can grow like a pure-play fertility leader.

1. How This Business Actually Works

CooperVision is a subscription business disguised as a medical device. A fitted contact-lens prescription becomes a recurring SKU that gets re-bought every day (MyDay, Clariti 1-day), two weeks, or month for years. Four players — Acuvue (J&J), Alcon, CooperVision, Bausch+Lomb — control almost the entire $10B+ global market. Switching costs are real: the patient's eye is fit to a specific lens curvature and material, and the eye-care professional writes the Rx. That combination produces price/mix of roughly 2–3 points per year without volume loss.

The incremental dollar of CVI profit comes from trade-up, not new wearers. Volume growth in contact lenses tracks population plus low-single-digit penetration. The real margin engine is category mix: moving wearers from monthly hydrogels into daily silicone hydrogels into specialty (torics/multifocals/myopia management). Dailies are 4–6x the annual revenue of a monthly at similar margins; torics add another layer because astigmatism is growing and harder to copy. Myopia management (MiSight, the only FDA-approved lens slowing childhood myopia progression) is the real optionality — a narrow clinical indication that could convert into a recurring pediatric category.

The bottleneck is manufacturing, not demand. Single-use dailies require enormous cast-molding capacity, and CVI has spent a decade building it — capex has run $300–420M annually, around 9% of sales, well above medtech peers at 3–5%. That capex is both the moat (capacity is a multi-year head start) and the tax on reported FCF. Free cash flow conversion runs close to 55% of EBITDA — respectable, not spectacular.

CooperSurgical is a different animal. It's an acquired collection of IVF consumables, surgical instruments, genomics, and one oversized asset — Paragard, the only hormone-free IUD in the US (~17% share, very high contribution margin). Paragard is both the crown jewel and the single point of failure: any FDA approval of a generic hormone-free IUD would reprice the franchise. The fertility portfolio has genuine scale across the IVF cycle (media, incubators, cryostorage, genomics) but competes with Vitrolife, Merck KGaA's portfolio, and Hamilton Thorne — an oligopoly, but a messier one than contact lenses.

2. The Playing Field

Cooper sits between the true compounders (Edwards, Hologic) and the distressed (Bausch+Lomb), with Alcon as the direct scale analog. The peer set shows what "good" looks like in medical devices — and it's not just gross margin.

Three things this reveals. First, Cooper's GAAP margin is artificially low — amortization of acquired intangibles knocks roughly seven points off reported operating margin. Non-GAAP OM near 25% is the real economic margin, which lines up with Alcon and sits about six points below Hologic. Second, the ROIC gap to Edwards and Hologic is structural, not a choice. Those businesses have narrower franchises (TAVR, breast diagnostics) that reinvest less at higher returns; Cooper has been a buyer of goodwill. Third, Bausch+Lomb shows what the losing end of this industry looks like — same gross margin as Cooper, one-tenth the operating margin, consistent losses. Eyecare is a good business, but only at scale and with manufacturing discipline.

The peer Cooper should be measured against is Alcon. Same revenue mix logic (vision care plus surgical), same capex intensity, same customer channel. Alcon trades richer on EV/EBITDA because its surgical business (IOLs, phaco equipment) has higher pricing power than contact lenses — and because investors still reward its 2019 spin-off transformation story.

3. Is This Business Cyclical?

Short answer: modestly cyclical around elective procedures and premium trade-up; dramatically cyclical around M&A integration. The consumable lens base is recession-resistant — people still wore glasses and contacts in 2009 and 2020 — but margins get hit by two levers: trade-up pauses (consumers defer premium dailies for cheaper monthlies) and FX (about 55% of revenue is non-US).

The two real stress tests tell different stories. The 2005–2008 Ocular Sciences integration (doubled revenue, crushed margin to 5.8%) was self-inflicted and took three years to repair — it's a warning about aggressive M&A, not a cycle signal. COVID 2020 is the cleaner cycle read: revenue dropped 8%, operating margin fell about 700bp, elective eye exams paused, IUD insertions were deferred, fertility cycles postponed. Both lines fully recovered within four to six quarters. The resilience read-through: roughly 65–70% of revenue (core contact-lens base) barely moved; all the volatility was in the elective and premium tail.

Where the cycle actually hits: (1) Fertility cycle volume — IVF is heavily out-of-pocket, so consumer-confidence sensitive, especially in China/APAC (Q1 FY26 Asia-Pacific down 4%; fertility in China weak, partly attributed to the Year of the Snake demographic pattern). (2) Premium lens trade-up — slower mix-up in recessions is a margin story, not a volume story. (3) FX — a strong dollar cuts reported growth by 3–5 points in some years. (4) Rate cycles flow through roughly $2.5B of long-term debt (interest expense jumped from $23M in FY21 to $114M in FY24).

4. The Metrics That Actually Matter

Stop looking at GAAP EPS. Cooper's economic engine shows up in five numbers — and most of them are not in the headline tables.

CVI organic growth is the single number that drives the stock. When it was 7–9% (FY2022–FY2024), Cooper traded at 25–30x forward non-GAAP EPS and sell-side models assumed a long runway. FY25 and guided FY26 organic growth of 4.5–5.5% is the critical inflection — if 5% is the new steady state, this is a 15–20x business, not a 25x business. Q1 FY26 came in at 3% organic on tough comps with currency help; the next three quarters decide the multiple.

Paragard is the hidden concentration. Back-of-the-envelope, Paragard is roughly $200M of revenue at a very high incremental margin, so it punches well above its revenue weight on EBITDA. It's the only hormone-free IUD in the US. A generic approval would not just compete on price — it would remove a structural gross margin contributor in CSI. Monitor the FDA approval pipeline for pending hormone-free IUD applications.

Non-GAAP operating margin is the real P&L. GAAP operating margin of 16.7% in FY25 is suppressed by $377M of amortization on acquired intangibles — a non-cash charge that will decline mechanically over the next decade. Non-GAAP OM of roughly 25% is both historically stable and the number guidance is given in. Decomposing: contact lens margin is high-20s, surgical mid-20s, corporate drag of ~2 points.

5. What I'd Tell a Young Analyst

Don't confuse the lens business with the roll-up. CooperVision is a genuine oligopoly with pricing power, capacity moats, and a multi-decade trade-up runway into dailies and myopia management. Value it like Alcon's vision segment. CooperSurgical is execution-dependent — the IVF integration has been competent but unspectacular, and Paragard is one FDA decision away from a reset. Don't pay the same multiple for both.

The GAAP-vs-non-GAAP gap is real. $377M of amortization drops off over roughly a decade; that's a mechanical EPS tailwind that doesn't require operational execution. Analysts who anchor on reported net income and miss this will conclude Cooper is a 30x stock when it's closer to a 15x stock on cash earnings.

What would genuinely change the thesis — either way. Bull case flips in motion: MyDay MiSight ramps internationally (turning myopia management from a $100M niche into a $500M+ category) and silicone hydrogel daily capacity comes fully online and lifts margin 200bp. Bear case flips: a second FDA-approved hormone-free IUD enters the US; e-commerce private-label dailies (already about one-third of CVI revenue) pressure branded pricing; CVI organic growth settles at 3% instead of 5%.

What the market is most likely misreading right now. The stock is down 22% over 12 months on what the market is treating as a structural slowdown. The data suggest something milder: tough comps, China weakness, tariff drag on gross margin, and a reorg that temporarily muddies the P&L. If organic growth stabilizes at 5% and non-GAAP OM expands to 27%+ as guided, this is a mid-cycle buy. If organic growth breaks below 4% while BLCO-style e-commerce pricing pressure shows up, the re-rating isn't done. The FY26 quarters are the call.